FLT3-ITD Allele Frequency Is an Independent Prognostic Factor for Poor Outcome in FLT3-ITD-Positive AML Patients

Nevine F Shafik1, Amira D Darwish2, Rasha Mahmoud Allam3

  • 1Clinical Pathology and Oncologic Laboratory Medicine Department, National Cancer Institute, Cairo University, Egypt.

Abstract

Insights

High allelic ratios (ARs) and allelic frequencies (AFs) of FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutations in acute myeloid leukemia (AML) correlate with poorer survival. These FLT3-ITD characteristics, along with high leukocyte counts and splenomegaly, are key prognostic factors.

Area of Science:

  • Hematology
  • Molecular Genetics
  • Oncology

Background:

  • FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) is a key genetic alteration in acute myeloid leukemia (AML).
  • FLT3-ITD mutations exhibit diverse allelic ratios (ARs) and duplicated sequence sizes.
  • Understanding the prognostic impact of FLT3-ITD ARs and allelic frequency (AF) is crucial for AML patient outcomes.

Purpose of the Study:

  • To investigate the prognostic significance of FLT3-ITD allelic ratios (ARs), allelic frequencies (AFs), and allele sizes in de novo acute myeloid leukemia (AML).

Main Methods:

  • Analysis of 117 de novo AML patients with FLT3-ITD mutations.
  • Stratification of patients based on high (>0.64) versus low FLT3-ITD ARs.
  • Evaluation of the association between FLT3-ITD characteristics and overall survival.

Main Results:

  • High FLT3-ITD AR (≥0.64) and AF (≥0.5) were significantly linked to reduced overall survival.
  • Patients with high FLT3-ITD AR had a median survival of 0.625 months compared to 1.020 months for those with low AR (P=.041).
  • NPM1 mutations did not confer a favorable prognosis in patients with low-level FLT3-ITD mutations.

Conclusions:

  • Elevated FLT3-ITD allelic frequency and ratio are independent prognostic indicators of poor outcome in AML.
  • Initial high total leukocyte count, FLT3-ITD AF, and splenomegaly are critical prognostic factors for FLT3-ITD-positive AML patients.

Related Concept Videos